Related Experiment Videos
Silent myocardial ischemia. A clinical perspective
1Department of Medicine, Veterans Affairs Medical Center, Fresno, Calif.
Insights
Silent myocardial ischemia is common in coronary artery disease patients and predicts worse outcomes. Current anti-ischemic therapies reduce silent ischemia episodes but do not improve prognosis.
Area of Science:
- Cardiology
- Ischemic Heart Disease
Background:
- Silent myocardial ischemia is more prevalent than symptomatic angina in coronary artery disease (CAD).
- Both increased myocardial oxygen demand and coronary vasomotor tone abnormalities contribute to silent ischemia.
- Over 40% of stable angina patients experience frequent silent ischemic episodes.
Purpose of the Study:
- To evaluate the role of silent ischemia in patients with coronary artery disease.
- To assess the impact of silent ischemia on adverse cardiac events and mortality.
- To determine if anti-ischemic therapy targeting total ischemic burden improves prognosis.
Main Methods:
- Review of recent data on silent myocardial ischemia prevalence in CAD.
- Analysis of factors contributing to the genesis of silent ischemia.
- Evaluation of studies on anti-ischemic drug efficacy in reducing silent ischemic episodes and their prognostic impact.
Main Results:
- Silent myocardial ischemia occurs frequently in CAD, exceeding anginal episodes.
- The presence of silent ischemia is a predictor of increased risk for coronary events and cardiac death.
- While anti-ischemic drugs reduce silent ischemia duration and frequency, no study has shown improved prognosis.
Conclusions:
- Silent myocardial ischemia is a significant clinical issue in CAD with prognostic implications.
- Therapeutic strategies should consider controlling the total ischemic burden.
- Current anti-ischemic treatments effectively reduce silent ischemia burden but lack proven prognostic benefit.
Abstract:
Silent myocardial ischemia has been shown to occur far more frequently than anginal episodes in patients with coronary artery disease. Both an increase in myocardial oxygen demand and abnormalities of coronary vasomotor tone appear to play a significant role in the genesis of silent ischemia. Recent data show that in excess of 40% of patients with stable angina have frequent episodes of silent ischemia. The presence of silent ischemia predicts an increased risk of coronary events and cardiac death. Based on these data, it has been proposed that anti-ischemic therapy should be directed toward control of total ischemic burden. Although several recent studies have demonstrated efficacy of various antianginal drugs in reducing the number and duration of silent ischemic episodes, none has demonstrated beneficial effect on the associated adverse prognosis.